Our Publications

Publications at Pubmed

 

1991

  1. Hatzichristou DG, Goldstein I. Arterial bypass surgery for impotence. Current Opinion in Urology, 1(2): 144-148, 1991.

1993

  1. Hatzichristou DG, Goldstein I, Kasznica J, Quist W.  The native venous architecture is preserved in an arterialized deep dorsal vein graft for arteriogenic impotence: a case report. J Urol. 1993 Apr; 149(4): 851-5.
  2. Hatzichristou DG, Goldstein I.  Penile microvascular arterial bypass surgery. Atlas Urologic Clinics of North America, 1(1): 39-60, 1993.
  3. Hatzichristou DG, Goldstein I. Penile microvascular arterial bypass: Indications and surgical considerations. Surgery Annual, 27(2): 207-229, 1993.

1994

  1. Chiu AW, Azadzoi KM, Hatzichristou DG, Siroky MB, Krane RJ, Babayan RK. Effects of intra-abdominal pressure on renal tissue perfusion during laparoscopy. J Endourol. 1994 Apr; 8(2): 99-103.
  2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. J Clin Epidemiol. 1994 May; 47(5): 457-67.
  3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994 Jan; 151(1): 54-61.
  4. Goldstein I, Hatzichristou DG. Preface to the special issue on Neurogenic Impotence. Sexuality and Disability, 12: 3-4, 1994.
  5. Hatzichristou DG, Bertero E, Goldstein I. Decision making in the evaluation of impotence: The patient's profile-oriented algorithm. Sexuality and Disability, 12: 29-37, 1994.
  6. Hatzichristou DG, Goldstein I, Quist WC. Preexisting vascular pathology in donor and recipient vessels during penile microvascular arterial bypass surgery. J Urol. 1994 May; 151(5): 1217-24.
  7. Kaufman JM, Hatzichristou DG, Mulhall JP, Fitch WP, Goldstein I. Impotence and chronic renal failure: a study of the hemodynamic pathophysiology. J Urol. 1994 Mar; 151(3): 612-8.
  8. Pescatori ES, Hatzichristou DG, Namburi S, Goldstein I.  A positive intracavernous injection test implies normal veno-occlusive but not necessarily normal arterial function: a hemodynamic study. J Urol. 1994 May; 151(5): 1209-16.

1995

  1. Hatzichristou DG, Omata S, Constantinou CE.  New method for direct stiffness measurement of the corpora cavernosa. Int J Impot Res. 1995 Dec; 7(4): 221-31.
  2. Hatzichristou DG, Saenz de Tejada I, Kupferman S, Namburi S, Pescatori ES, Udelson D, Goldstein I. In vivo assessment of trabecular smooth muscle tone, its application in pharmaco-cavernosometry and analysis of intracavernous pressure determinants. J Urol. 1995 Apr; 153(4): 1126-35.

1996

  1. Hatzichristou DG. Management of voiding, bowel and sexual dysfunction in multiple sclerosis: towards a holistic approach. Sexuality and Disability, 14(1): 3-7, 1996.

1998

  1. Hatzichristou DG, Hatzimouratidis K, Ioannides E, Yannakoyorgos K, Dimitriadis G, Kalinderis A. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers: reproducibility, evaluation criteria and the effect of sexual intercourse. J Urol. 1998 Jun; 159(6): 1921-6.
  2. Hatzichristou DG. Current treatment and future perspectives for erectile dysfunction. Int J Impot Res. 1998 May; 10 Suppl 1: S3-13.
  3. Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane RJ, Saenz de Tejada I, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part III--Clinical considerations of penile hemodynamic and rigidity erectile responses. Int J Impot Res. 1998 Jun; 10(2): 89-99.
  4. Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane RJ, Saenz de Tejada I, Goldstein I.  Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part II-Clinical implications of penile buckling. Int J Impot Res. 1998 Mar; 10(1): 25-35.
  5. Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane J, Saenz de Tejada IS, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part I--Clinical implications of penile tissue mechanical properties. Int J Impot Res. 1998 Mar; 10(1): 15-24.

1999

  1. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Ioannidis E, Yannakoyorgos K, Kalinderis A.  Hemodynamic characterization of a functional erection. Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. Eur Urol. 1999; 36(1): 60-7.

2000

  1. Goulas A, Hatzichristou DG, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Papakonstantinou E. Benign hyperplasia of the human prostate is associated with tissue enrichment in chondroitin sulphate of wide size distribution. Prostate. 2000 Jul 1; 44(2): 104-10. 
  2. Goulas A, Papakonstantinou E, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Hatzichristou DG.  Tissue structure-specific distribution of glycosaminoglycans in the human penis. Int J Biochem Cell Biol. 2000 Sep; 32(9): 975-82.
  3. Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol. 2000 Oct; 164(4): 1197-200.

2001

  1. Hatzichristou DG, Apostolidis A, Tzortzis V, Hatzimouratidis K, Ioannides E, Yannakoyorgos K. Glansectomy: an alternative surgical treatment for Buschke-Lowenstein tumors of the penis. Urology. 2001 May; 57(5): 966-9.
  2. Hatzichristou DG, Apostolidis A, Tzortzis V, Hatzimouratidis K, Kouvelas D. Effects of oral phentolamine, taken before sleep, on nocturnal erectile activity: a double-blind, placebo-controlled, crossover study. Int J Impot Res. 2001 Oct; 13(5): 303-8.
  3. Hatzichristou DG, Pescatori ES. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU International 2001 Oct; 88 Suppl 3: 11-7.
  4. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res. 2001; 13 Suppl 6: S1-S10.

2002

  1. Apostolidis A, Fowler CJ. Single-incision vasectomy induced perineal nerve damage: diagnosis by cortical evoked potentials from the perineal nerve. BJU Int 2002 (ηλεκτρονική δημοσίευση, Αύγουστος 2002).
  2. Argyriou A, Hatzichristou DG. Recent advances in therapy for impotence. Hospital Prescriber Europe, 2002; 3: 16-17.
  3. Hatzichristou D, Hatzimouratidis K, Bekas M, Apostolidis A, Tzortzis V, Yannakoyorgos K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol. 2002 Aug; 168(2): 615-20.
  4. Hatzichristou D, Salpiggidis G, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Saripoulos D.  Management strategy for arterial priapism: therapeutic dilemmas. J Urol. 2002 Nov; 168(5): 2074-7.
  5. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Ioannidis E. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol. 2002 Mar; 167(3): 1367-70.
  6. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D.  Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002 Sep; 60(2 Suppl 2): 28-38.
  7. Nehra A, Pryor J, Althof SE, Andersson K, Carson C, Giuliano F, Hatzichristou D, Hedlund H, Meuleman E, Montorsi F, Porst H, Riley A, Saenz de Tejada I, Stief C, Wespes E. Second International Conference on management of erectile dysfunction: new perspectives on treatment. Int J Impotence Res 2002, 14: S1-S5.
  8. Wagner G, Claes H, Costa P, Cricelli C, De Boer J, Debruyne FM, Dean J, Dinsmore WW, Fitzpatrick JM, Ralph DJ, Hackett GI, Heaton JP, Hatzichristou DG, Mendive J, Meuleman EJ, Mirone V, Montorsi F, Raineri F, Schulman CC, Stief CG, Von Keitz AT, Wright PJ; Lygon Arms Group.  A shared care approach to the management of erectile dysfunction in the community. Int J Impot Res. 2002 Jun; 14(3): 189-94.
  9. Wespes E, Amar E, Hatzichristou D, Montorsi F, Pryor J, Vardi Y; European Association of Urology Guidelines on erectile dysfunction. Eur Urol. 2002 Jan; 41(1): 1-5.

2003

  1. Apostolidis A, Fowler CJ. Evaluation and treatment of the autonomic disorders of the urogenital system. Semin Neurol 2003; 23(4): 443-452.
  2. Hatzichristou DG, Hatzimouratidis K, Tzortzis V, Apostolidis A, Bekos A, Ioannidis E. Normal hemodynamic parameters do not always predict the presence of a rigid erection: a quantitative assessment of functional erectile impairment. Int J Impot Res. 2003 Apr; 15(2): 99-104.
  3. Hatzichristou DG, Tzortzis V, Hatzimouratidis K, Apostolidis A, Moysidis K, Panteliou S. Protective role of the glans penis during coitus. Int J Impot Res. 2003 Oct; 15(5): 337-42.
  4. Kirchhof K, Apostolidis A, Mathias CJ, Fowler CJ. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. Int J Impot Res. 2003 Aug; 15(4): 293-8.
  5. Stanopoulos I, Hatzichristou D, Tryfon S, Tzortzis V, Apostolidis A, Argyropoulou P.  Effects of sildenafil on cardiopulmonary responses during stress. J Urol. 2003 Apr; 169(4): 1417-21.

2004

  1. Apostolidis AN, Yiangou Y, Brady CM, Ford AP, Baecker PA, Jacques TS, Freeman A, Fowler CJ, Anand P. Endothelial nitric oxide synthase expression in neurogenic urinary bladders treated with intravesical resiniferatoxin. BJU Int. 2004; 93(3): 336-340.
  2. Brady C, Apostolidis A, Yiangou Y, Baecker PA, Ford AP, Freeman A, Jacques TS, Fowler CJ, Anand P. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX). Eur Urol 2004, 46(2): 247-53.
  3. Brady CM, Apostolidis A, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, Anand P. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity (NDO) following intravesical resiniferatoxin treatment. BJU International 2004, 93(6): 770-776
  4. Carson C, Giuliano F, Goldstein I, Hatzichristou D, Hellstrom W, Lue T, Montorsi F, Munarriz R, Nehra A, Porst H, Rosen R.  The 'effectiveness' scale-therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res. 2004; 16(3): 207-13.
  5. Carson CC,  Hatzichristou DG, Carrier S, Lording D,  Lyngdorf P, Aliotta P, Auerbach S,  Murdoch M, Azam U, McBride T,9 Colopy MW for the Patient Response With Vardenafil in Sildenafil Non-Responders (PROVEN) Study Group. Erectile response with vardenafil in sildenafil non-responders: a multicenter, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int, 2004; 94; 1301-1309.
  6. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H. The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men. Eur Urol. 2004 May; 45(5): 634-41.
  7. Hatzichristou DG, Rosen R, Broderick G, Clayton A, Cuzin B, Derogatis L, Litwin M, Meuleman E, O’Leary M,  Quirk F, Sadovsky R, Seftel A. Clinical Evaluation and Management Strategy of Sexual Dysfunction in Men and Women. J Sex Med. 2004; 1(1): 49-57.
  8. Hatzichristou DG: Comments from Dimitrios Hatzichristou, Reviews and Education Editor. J Sex Med. 2004; 1(1): 3.
  9. Hatzimouratidis K, Hatzichristou DG. Treatment Options for Erectile Dysfunction in Patients Failing Oral DrugTherapy. EAU Update Series 2004, 2; 75-83.
  10. Kalyvas KD, Kotakidou R, Trantos A, Yannakoyorgos K, Hatzichristou DG.  Paratesticular well-differentiated, adipocytic type liposarcoma presenting as inguinal hernia. Urol Int. 2004; 72(3): 264-8.
  11. Lue TF, Giuliano F, Montorsi F, Rosen R, Andersson KE, Althof  S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J,  Saenz de Tejada I, Shabsigh R, Wagner G. Summary of the Recommendations on Sexual Dysfunctions in Men. . J  Sex Med. 2004; 1(1): 6-23.

2005

  1. Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P. Capsaicin receptor TRPV1 in the urothelium of neurogenic human bladders and the effect of intravesical resiniferatoxin. Urology 2005; 65(2): 400-5.
  2. Apostolidis A, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int. 2005; 96(6): 917-8.
  3. Apostolidis A, Fowler CJ. Intravesical vanilloids: state of art and future possibilities. Urodynamica 2005; 15(2): 87-93.
  4. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford APDW, Davis JB, Dasgupta P , Fowler CJ, Anand P . Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intra-detrusor injections of Botulinum toxin for human detrusor overactivity. J Urol 2005; 174(3):977-82; discussion 982-3.
  5. Hatzichristou D, Apostolidis A, Bekos A, Tzortzis V, Ioannidis E, Yannakoyorgos K. Sildenafil failures may be due to inadequate instructions and follow-up: a study on 100 non-responders. Eur Urol, 2005; 47(4): 518-22.
  6. Hatzichristou D, Tsimtsiou Z. Prevention and management of cardiovascular disease and erectile dysfunction: towards a common, patient-centered, care model. American Journal of Cardiology, 2005; 96 (suppl), 80M-84M.
  7. Hatzichristou DG, Aliotta P, Auerbach S, Barkin J, Lording D, Murdock M, Wilkins HJ, McBride T, Colopy MW, Carson CC for the PROVEN Study Group.  Erectile response to vardenafil in men with a history of non-response to sildenafil: A time-from-dosing descriptive analysis.  Clin Ther 2005; 27: 1452-1461.
  8. Hatzichristou DG, Apostolidis A, Bekos A, Tzortzis V, Ioannides E, Yannakoyorgos K. Sildenafil failures may be due to inadequate instructions and follow-up: a study on 100 non-responders. Eur Urol 2005; 47(4): 518-22.
  9. Hatzichristou DG, Cuzin B, Martin-Morales A, Buvat J, Porst H, Laferriere N, Bandel T.J, Montorsi F. Vardenafil Improves Satisfaction Rates, Depressive Symptomatology, and Self-Confidence in a Broad Population of Men with Erectile Dysfunction.  J Sex Med. 2005; 2 (1), 109-116.
  10. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V,
  11. Hatzimouratidis K, Ioannidis E. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol. 2005 Apr; 47(4): 518-22;
  12. Hatzichristou DG, Vardi Y, Papp G, Pushkar D, Basson BR,  Kopernicky V. Effect of Tadalafil (CialisTM) on Sexual Timing Behavioural Patterns in Men with Erectile Dysfunction: Integrated Analysis of Randomised, Placebo-Controlled Trials. J Urol.2005; 174: 1356-1359.
  13. Hatzichristou DG. Phosphodiesterase 5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION): Coincidence or Causality? J Sex Med 2005; 2: 751-758.
  14. Hatzimouratidis K, Hatzichristou D. A Comparative Review of the Options for Treatment of Erectile Dysfunction:  Which Drug for Which Patient? Drugs; 65(12): 1621-1650, 2005.
  15. Hatzimouratidis K, Hatzichristou D. Vardenafil in the treatment of erectile dysfunction: a review of clinical data and personal clinical experience. Ageing Health, Dec 2005.
  16. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005; 65(12): 1621-50.
  17. Kostis, JB, Jackson, G,  Rosen, R, Barrett-Connor, E,  Billups, K,  Burnett, AL, Carson, C,  Cheitlin, M, DeBusk, R, Fonseca, V,  Ganz, P,  Goldstein, I, Guay, A,  Hatzichristou, D,  Hollander, JE, Hutter, A,  Katz, S,  Kloner, RA, Mittleman, M, Montorsi, F, Montorsi, P, Nehra, A,  Sadovsky, R,  Shabsigh, R. Sexual Dysfunction and Cardiac Risk:The 2nd Princeton Consensus Conference. Am J Cardiol, 2005; 96(2): 313-21.
  18. Mallis D,  Moysidis K,  Nakopoulou E,  Papaharitou S,  Hatzimouratidis K, Hatzichristou D. Psychiatric morbidity is frequently undetected in patients with erectile dysfunction. J Urol 2005; 174: 1913-1916.
  19. Papaharitou S, Nakopoulou E, Kyrana PS, Iraklidou M, Athanasiadis L, Hatzichristou D. Women’s sexual concerns: data analysis from a help-line. J Sex Med, 2005; 2: 652-657.
  20. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO) to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174(3): 984-989.
  21. Zoumpos I, Hatzimouratidis K, Katsikas V. Internet resources for urologists. BJU Int. 2005 Dec; 96(8): 1185-91.

2006

  1. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49(4): 644-5
  2. Apostolidis A, Gonzales GE, Fowler CJ. Effect of intravesical resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters and quality of life of patients with urodynamic increased bladder sensation. Eur Urol 2006; 50(6): 1299-305.
  3. Apostolidis A, Haferkamp A, Aoki R. Understanding the role of Botulinum toxin A in the treatment of the overactive bladder – more than just muscle relaxation. Eur Urol supplements 2006; 5: 670-678.
  4. Athanasiadis L, Papaharitou S, Salpiggidis G, Tsimtsiou Z, Nakopoulou E, Kirana PS, Moisidis K, Hatzichristou D. Educating physicians to treat erectile dysfunction patients: development and evaluation of a course on communication and management strategies. J Sex Med. 2006 Jan; 3(1):47-55.
  5. Broderick GA, Donatucci CF, Hatzichristou D, Torres LO, Valiquette L, Zhao Y, Loughney K, Sides GD, Ahuja S. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. J Sex Med. 2006 Jul; 3(4): 668-75.
  6. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Effective Erectile Dysfunction (ED) Treatment Enables Men to Enjoy Better Sex: The Importance of Erection Hardness, Psychological Well-Being, and Partner Satisfaction (2006) European Urology, Supplements, 5 (13), pp. 761-766.
  7. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. The Role of Erection Hardness in Determining Erectile Dysfunction (ED) Treatment Outcome (2006) European Urology, Supplements, 5 (13), pp. 767-772.
  8. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Erectile Dysfunction and Sexual Satisfaction: New Perspectives (2006) European Urology, Supplements, 5 (13), pp. 759-760.
  9. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Psychological, Social, and Behavioural Benefits for Men Following Effective Erectile Dysfunction (ED) Treatment: Men Who Enjoy Better Sex Experience Improved Psychological Well-Being (2006) European Urology, Supplements, 5 (13), pp. 773-778.
  10. Dean, J., de Boer, B.-J., Graziottin, A., Hatzichristou, D., Heaton, J., Tailor, A. Partner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction (ED) (2006) European Urology, Supplements, 5 (13), pp. 779-785.
  11. Haro JM, Beardsworth A, Casariego J, Gavart S, Hatzichristou D, Martin-Morales A, Schmitt H, Mirone V, Needs N, Riley A, Varanese L, von Keitz A, Kontodimas S. Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study. J Sex Med. 2006 May; 3(3): 530-40.
  12. Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging. 2006; 1(4): 403-14.
  13. Hatzimouratidis K, Hatzichristou DG. Pharmacological treatment of erectile dysfunction: a 2005 update. European Pharmacotherapy 2006, 2-8.
  14. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. Eur Urol. 2006 Jul; 50(1): 126-32.
  15. Heaton JW, Hatzichristou D. Open to debate. The motion: there is a role for chronic treatment with PDE5-inhibitors. Eur Urol. 2006 Apr; 49(4): 749-53.
  16. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A (BoNT/A) and correlations with lower urinary tract symptoms (LUTS) and urodynamic changes. Eur Urol 49(3): 528-35.
  17. Kalsi V, Popat R, Apostolidis A, Kavia R, Odeyemi IAO, Dakin HA, Warner J, Elneil S, Fowler CJ, Dasgupta P. Cost-consequence analysis evaluating the use of Botulinum neurotoxin A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006; 49(3): 519-27.
  18. Mallis D, Moisidis K, Kirana PS, Papaharitou S, Simos G, Hatzichristou D. Moderate and severe erectile dysfunction equally affects life satisfaction. J Sex Med. 2006 May; 3(3): 442-9.
  19. McCullough AR, Carson CC, Hatzichristou D. A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction. Urology. 2006 Sep; 68(3 Suppl): 38-46.
  20. Papaharitou S, Athanasiadis L, Nakopoulou E, Kirana P, Portseli A, Iraklidou M, Hatzimouratidis K, Hatzichristou D. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline. Eur Urol. 2006 Mar; 49(3): 557-63.
  21. Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil BN, Smith PM, Wilkins HJ, Pommerville P; Vardenafil Study Group. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol. 2006 Nov; 50(5): 1086-94.
  22. Tsimtsiou Z, Hatzimouratidis K, Nakopoulou E, Kyrana E, Salpigidis G, Hatzichristou D. Predictors of physicians' involvement in addressing sexual health issues. J Sex Med. 2006 Jul; 3(4): 583-8.
  23. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: an update. Eur Urol. 2006 May; 49(5): 806-15.

2007

  1. Apostolidis A, Popat R, Harper M, Fowler CJ, Dasgupta P. Successful treatment with botulinum toxin A after failed augmentation ileocystoplasty. Nature Clinical Practice Urology 2007; 4(5): 280-4.
  2. Hatzichristou D, Haro JM, Martin-Morales A, von Keitz A, Riley A, Bertsch J, Belger M, Wolka AM, Beardsworth A; EDOS Group. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract. 2007 Nov; 61(11): 1850-62.
  3. Hatzimouratidis K. Re: Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. Eur Urol. 2007 Jan; 51(1): 278.
  4. Hatzimouratidis K. Epidemiology of male sexual dysfunction. Am J Mens Health. 2007 Jun; 1(2): 103-25.
  5. Hatzimouratidis K. Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link? Curr Urol Rep. 2007 Nov; 8(6): 482-90.
  6. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol. 2007 Jan; 51(1): 75-88.
  7. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions. J Sex Med. 2007 Jan; 4(1): 241-50.
  8. Hatzimouratidis K, Hatzichristou D. Testosterone and erectile function: an unresolved enigma. Eur Urol. 2007 Jul; 52(1): 26-8.
  9. Hatzimouratidis K, Koliakos N, Koutsogiannis I, Moisidis K, Giakoumelos A, Hatzichristou D. Removal of a detached head of the Brooks dilator from the corpora cavernosa during penile prosthesis implantation. J Sex Med. 2007 Jul; 4(4 Pt 2): 1179-81.
  10. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, Fowler CJ. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007; 62(5): 452-7.
  11. Kaplan SA, Hatzichristou D. Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Eur Urol. 2007 Nov; 52(5): 1523-7.
  12. Kirana PS, Nakopoulou E, Akrita I, Papaharitou S. Parents’ attitudes and health promoters’ views concerning adolescents’ sexual education. Sex Education 2007; 7(3): 265-276.
  13. Konstantinidou E, Apostolidis A, Kondelidis N, Tsimtsiou Z, Hatzichristou D, Ioannides E. Short-term efficacy of high supervisory intensity group pelvic floor training versus unsupervised home training for female stress urinary incontinence: a randomized pilot study. Neurourol Urodyn 2007; 26(4): 486-91.
  14. Konstantinidou E, Apostolidis A, Kondelidis N, Tsimtsiou Z, Hatzichristou D, Ioannides E. Short-term efficacy of group pelvic floor training under intensive supervision versus unsupervised home training for female stress urinary incontinence: a randomized pilot study. Neurourol Urodyn. 2007; 26(4): 486-91.
  15. Mitropoulos D, Papakonstantinou E, Aletras AJ, Kalinderis N, Zervas A, Hatzichristou D, Karakiulakis G. Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate. Eur Urol. 2007 Feb; 51(2): 447-56.
  16. Papaharitou S, Nakopoulou E, Kirana P, Giaglis G, Moraitou M, Hatzichristou D. Factors associated with sexuality in later life: An exploratory study in a group of Greek married older adults. Arch Gerontol Geriatr. 2007 May 24;
  17. Papaharitou S, Nakopoulou E, Moraitou M, Hatzimouratidis K, Hatzichristou D. Reproductive health and midwives: does occupational status differentiate their attitudes on assisted reproduction technologies from those of the general population? Hum Reprod. 2007 Jul; 22(7): 2033-9.
  18. Tsimtsiou Z, Kerasidou O, Efstathiou N, Papaharitou S, Hatzimouratidis K, Hatzichristou D. Medical students' attitudes toward patient-centred care: a longitudinal survey. Med Educ. 2007 Feb; 41(2):146-53.
  19. Tsimtsiou Ζ, Hatzimouratidis Κ, Nakopoulou Ε, Kyrana Ε, Salpigidis G, Hatzichristou D.  Predictors of physicians’ involvement in addressing sexual health issues. Journal of Sexual Medicine, 2007; 3: 583-8.
  20. Tsimtsiou Z, Papaharitou S, Nakopoulou E, Hatzichristou D, Derogatis LR: "Linguistic and cultural adaptation of the Derogatis Sexual Functioning Inventory-Αttitudes subscale in the Greek language", Archives of Hellenic Medicine 24 (4): 363-368 (Aug 2007).

2008

  1. Apostolidis A, Fowler CJ. The use of botulinum neurotoxin type A (BoNTA) in urology. J Neural Transm. 2008; 115(4): 593-605.
  2. Apostolidis A, Jacques TS, Freeman A, Kalsi V, Popat R, Gonzales G, Datta SN, Ghazi-Noori S, Elneil S, Dasgupta P, Fowler CJ. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol. 2008; 53(6): 1245-53.
  3. Bekos A, Arvaniti M, Hatzimouratidis K, Moysidis K, Tzortzis V, Hatzichristou D. The natural history of Peyronie's disease: an ultrasonography-based study. Eur Urol. 2008 Mar; 53(3): 644-50.
  4. Buvat J, Hatzichristou D, Maggi M, Farmer I, Martínez-Jabaloyas JM, Miller PJ, Schnetzler G. Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. BJU Int. 2008 Dec; 102(11): 1645-50.
  5. Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, Roger Aoki K. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol. 2008; 5(6): 319-28.
  6. Ferenidou F, Kapoteli V, Moisidis K, Koutsogiannis I, Giakoumelos A, Hatzichristou D. Presence of a sexual problem may not affect women's satisfaction from their sexual function. J Sex Med. 2008 Mar; 5(3): 631-9.
  7. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008 Feb; 25(2): 138-46.
  8. Hatzichristou D. Understanding individuals' response to erectile dysfunction. Int J Impot Res. 2008 Dec; 20 Suppl 2: S15-20.
  9. Hatzimouratidis K. Words of wisdom. Re: The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. Paick J-S, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh J-K, Kim SC. Eur Urol. 2008 Oct; 54(4): 946-7.
  10. Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs. 2008; 68(2): 231-50.
  11. Hatzimouratidis K, Moysidis K, Bekos A, Giakoumelos A, Hatzichristou D. What is adequate management to preserve erectile function after unilateral nerve-sparing radical prostatectomy? J Endourol. 2008 Sep; 22(9): 2029-31.
  12. Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol. 2008; 54(1): 181-7.
  13. Kirana P.S., Nakopoulou E., Papaharitou S., K. Moysidis K., Hatzimouratidis K., Salpigidis G. and Hatzichristou D. Presence of a sexual problem may not affect sexual satisfaction: results from the hospitalised and outpatients' profile and expectation study (HOPES). European Urology Supplements 2008 March; 7(3): 218.
  14. Papaharitou S, Nakopoulou E, Kirana P, Giaglis G, Moraitou M, Hatzichristou D. Factors associated with sexuality in later life: An exploratory study in a group of Greek married older adults. Arch Gerontol Geriatr. 2008 Mar-Apr; 46(2): 191-201.
  15. Papaharitou S, Nakopoulou E, Moraitou M, Tsimtsiou Z, Konstantinidou E, Hatzichristou D. Exploring sexual attitudes of students in health professions. J Sex Med. 2008 Jun; 5(6): 1308-16.

2009

  1. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ. Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus Report. Eur Urol. 2009; 55: 100-120.
  2. Apostolidis A, Kirana PS, Chiu G, Link C, Tsiouprou M, Hatzichristou D. Gender and Age Differences in the Perception of Bother and Health Care Seeking for Lower Urinary Tract Symptoms: Results from the Hospitalised and Outpatients' Profile and Expectations Study. Eur Urol. 2009; 56(6): 937-947.
  3. Hatzichristou D. Iñigo Sáenz de Tejada y Gorman - An aristocrat and pioneer in sexual medicine. Eur Urol. 2009 Jul; 56(1): 234-5.
  4. Hatzimouratidis K. Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms? Expert Opin Investig Drugs. 2009 Mar; 18(3): 245-54.
  5. Hatzimouratidis K. Editorial comment on: Smooth-muscle-specific gene transfer with the human maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol. 2009 Dec; 56(6): 1066.
  6. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009 Feb; 55(2): 334-47.
  7. Hatzimouratidis K, Hatzichristou DG. Phosphodiesterase type 5 inhibitors: unmet needs. Curr Pharm Des. 2009; 15(30): 3476-85.
  8. Howles S, Curry J, McKay I, Reynard J, Brading AF, Apostolidis A. Lack of effectiveness of botulinum neurotoxin A on isolated detrusor strips and whole bladders from mice and guinea-pigs in vitro. BJU Int. 2009, 104(10): 1524-9; discussion 1529-30.
  9. Jannini EA, Granata AM, Hatzimouratidis K, Goldstein I. Use and abuse of Rigiscan in the diagnosis of erectile dysfunction. J Sex Med. 2009 Jul;6(7):1820-9.
  10. Khan S, Kessler TM, Apostolidis A, Kalsi V, Panicker V, Roosen A, Gonzales G, Haslam C, Elneil S, Fowler CJ, Dasgupta P. What should a patient with refractory idiopathic detrusor overactivity know regarding botulinum neurotoxin type A (Botox®) injections? J Urol 2009, 181(4): 1773-8.
  11. Kirana PS, Papaharitou S, Athanasiadis L, Nakopoulou E, Salpiggidis G, Moysidis K, Pipilaki C, Hatzimouratidis K, Tzotstzis V, Portseli A, Iraklidou M, Apostolidis A, Bekos A, Hatzichristou D.  A conceptual framework for the evolution of sexual medicine and a model for the development of alternative sexual health services: 10-years experience of the Centre for Sexual and Reproductive Health. J Sex Med. 2009 Sep; 6(9): 2405-16.
  12. Kirana PS, Rosen R, Hatzichristou D. Subjective Well- being as a determinant of individuals’ responses to symptoms: Development of a biopsychosocial conceptual framework. Int J Clin Pract. 2009 Oct; 63(10):1435-45.
  13. Nakopoulou E, Kirana PS, Chiu G, Link C, Rosen R, Hatzichristou D. Level of bother and treatment seeking predictors among male and  female in-patients with sexual problems: A hospital-based study. J Sex Med. 2009 Nov 24.
  14. Nakopoulou E, Papaharitou S, Hatzichristou D. Patients' sexual health: a qualitative research approach on Greek nurses' perceptions. J Sex Med. 2009 Aug; 6(8): 2124-32.
  15. Roosen A, Apostolidis A, Elneil S, Khan S, Panicker J, Brandner S, Fowler CJ, Kessler TM. Cadherin-11 Up-Regulation in Overactive Bladder Suburothelial Myofibroblasts. J Urol. 2009 182(1): 190-5.
  16. Roosen A, Datta SN, Chowdhury RA, Patel PM, Kalsi V, Elneil S, Dasgupta P,  Kessler TM, Khan S, Panicker J, Fry CH, Brandner S, Fowler CJ,  Apostolidis A. Suburothelial myofibroblasts in the human overactive bladder and the effect of Botulinum neurotoxin type A treatment. Eur Urol 2009, 55: 1440-9. 
  17. Vardi Y, Levine LA, Chen J, Hatzimouratidis K, Sohn M. Is there a place for conservative treatment in Peyronie's disease? J Sex Med. 2009 Apr; 6(4): 903-9.

2010

  1. Datta SN, Roosen A, Pullen A, Popat R, Rosenbaum TP, Elneil S, Dasgupta P, Fowler CJ, Apostolidis A. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol. 2010; 184(6): 2578-85.
  2. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, Munarriz R, Lee SW. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010 Jan; 7(1 Pt 2): 524-40.
  3. Evangelia N, Kirana PS, Chiu G, Link C, Rosen R, Hatzichristou D. Level of bother and treatment-seeking predictors among male and female in-patients with sexual problems: a hospital-based study. J Sex Med. 2010 Feb; 7(2 Pt 1): 700-11.
  4. Hatzimouratidis K. Can we cure erectile dysfunction? Eur Urol. 2010 Aug; 58(2): 249-50.
  5. Hatzimouratidis K. Re: Penile sonographic and clinical characteristics in men with Peyronie's disease. Eur Urol. 2010 May; 57(5): 918.
  6. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E; European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010 May; 5.
  7. Nakopoulou E., Kirana P.S., Chiu G, Link C., Rosen R.,  Hatzichristou D. Level of Bother and Treatment-Seeking Predictors Among Male and Female in-Patients with Sexual Problems: A Hospital-Based Study. J Sex Med 2010 Feb; 7(2): 700-11.
  8. Oeconomou A, Apostolidis A. Current status of Botulinum toxin for neurogenic bladder dysfunction. Curr Bladder Dysfunc Rep 2010; 5: 87-97
  9. Papaharitou S., Nakopoulou E., Moraitou M., Hatzichristou D. Assisted reproduction and midwives: student and certified midwives' educational needs on reproductive biology. Sex Reprod Healthc. 2010 Nov; 1(4): 163-8.

2011

  1. Apostolidis A. Neuromodulation for intractable OAB. Neurourol Urodyn. 2011 Jun; 30(5): 766-70.
  2. Apostolidis A. Novel insights and targets for managing overactive bladder. J Urol. 2011 Jun; 185(6): 2018-20.
  3. Apostolidis A. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins. Expert Opin Pharmacother. 2011 May; 12(7): 1029-39.
  4. Apostolidis A. Antimuscarinic treatment for overactive bladder symptoms: an all-time classic, yet still a clinical and basic challenge. Eur Urol. 2011 Mar; 59(3): 356-8.
  5. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.  Eur Urol. 2011 Oct; 60(4): 809-25.
  6. Goulis DCh, Mintziori G, Koliakos N, Hatzichristou D, Papadimas I, Hatzimouratidis K, Goulis DG. Inhibin B and anti-Müllerian hormone in spermatic vein of subfertile men with varicocele. Reprod Sci. 2011 Jun; 18(6): 551-5.
  7. Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, Apostolidis A, Hamid R, Dasgupta P, Kessler TM, Fowler CJ. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011 Apr; 185(4): 1344-9.
  8. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011 Oct; 60(4): 784-95.

2012

  1. Apostolidis A. Taming the cannabinoids: new potential in the pharmacologic control of lower urinary tract dysfunction. Eur Urol. 2012 Jan;61(1):107-9; discussion 109-11.
  2. Apostolidis A. Treatment of overactive bladder with botulinum toxin: are there more challenges to deal with? Eur Urol. 2012 Sep; 62(3): 515-7.
  3. Apostolidis A, de Nunzio C, Tubaro A. What determines whether a patient with LUTS seeks treatment? ICI-RS 2011. Neurourol Urodyn. 2012 Mar;31(3):365-9.
  4. Hatzichristou D. Post-radical prostatectomy erectile function: the five ws and the h. Eur Urol. 2012 Aug; 62(2): 287-9.
  5. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y, Wespes E. EAU Guidelines on Penile Curvature. Eur Urol. 2012 Sep; 62(3): 543-52.
  6. Tsimtsiou Z, Benos A, Garyfallos AA, Hatzichristou D. Predictors of physicians' attitudes toward sharing information with patients and addressing psychosocial needs: a cross-sectional study in Greece. Health Commun. 2012; 27(3): 257-63.